Astra sinks Advent's USD 7.6bn buyout of biotech Sobi

Astrazeneca was the reason that the acquisition of Swedish pharmaceutical firm Sobi failed, as the pharmaceutical giant itself wanted certain assets from the Swedish company, sources say.


Astrazeneca Plc effectively blocked a USD 7.6bn takeover of Swedish Orphan Biovitrum AB by withholding its 8 percent stake in the drugmaker from a buyout offer by Advent International and Singapore wealth fund GIC, according to people familiar with the situation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs